Estrógenos y enfermedad de Alzheimer: Bases, promesas y realidades

Medicina Clinica

Volumn 114, Issue 19, 2000, Pages 747-755

  Martínez Lage, José Manuel ^a   Oliveros Cid, Antonio ^a   Martínez Lage, Pablo ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b Ctro Psicogeriatrico Landazabal   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN DERIVATIVE;

ALZHEIMER DISEASE; COGNITION; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MENARCHE; PATHOPHYSIOLOGY; POSTMENOPAUSE; REVIEW; NERVE DEGENERATION;

ALZHEIMER DISEASE; COGNITION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENARCHE; POSTMENOPAUSE;

EID: 0034690502     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(00)71421-7     Document Type: Article

References (173)

1. 0 ed.) Filadelfia: Lippincot Williams and Wilkins, 1999; 423-439.
2. Monk D, Brodarty H. Use of estrogens for the prevention and treatment of Alzheimer's disease, Dement Geriatr Cogn Disord 2000; 11: 1-10.
3. Andersen K, Launer LJ, Dewey ME, Letteneur L, Ott A, Copeland JR Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. Neurology 1999; 53: 1992-1997.
4. Evans D, Ganguli M, Harris T, Kawas C, Larson EB. Women and Alzheimer disease. Alzheimer Disease and Related Disorders 1999; 13: 187-189.
5. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD et al. Evidence for an interaction between apolipoprotein E genotype, gender and Alzheimer disease. Alzheimer Disease and Related Disorders 1999; 13: 216-221.
6. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD et al. Gender difference in apolipoorotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 1996; 4: 803-811.
7. Van-Dujin CM, Meijer H, Witteman JCM, Havekes LM, De Knijiff P, Van Broeckhoven C et al. Estrogen, apolipoprotein E and the risk of Alzheimer's Disease. Neurobiol Aging 1996; 17 (Supl): S79.
8. Letteneur L, Launer LJ, Andersen K, Dewey ME, Ott A, Copeland JR. Educational attainment and the risk for Alzheimer's disease: EURODEM pooled analyses. Am J Epidemiol 1999. En prensa.
9. Birge SJ. Hormones and the aging brain. Geriatrics 1998; S28-S30.
10. Nee LE, Lippa CF. Alzheimer's Disease in 22 Twin Pairs-13 year follow-up: hormonal, infectious and traumatic factors. Dement Geriatr Cogn Disord 1999; 10: 148-151.
11. Doraiswamy PM, Krishen A, Martin WL, Sylvester J, Garman RL, Metz A et al. Gender, concurrent estrogen use and cognition in Alzheimer's disease. Int J Geriat Psychopharmacol 1997; 34-37.
12. Filley CM. Alzheimer's disease in women. Am J Obstet Gynecol 1997; 1 1-7.
13. McPherson S, Back C, Buckwalter JG, Cummings JL. Gender-related cognitive deficits in Alzheimer's disease. Internat Psychogeriatrics 1999; 2: 117-122.
14. Muñoz DG, Ganapathy GR, Eliaszin M, Hachinski V Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease. Arch Neurol 2000; 57: 85-89.
15. Shumaker SA, Rapp SR. Hormone therapy in dementia prevention: the Women's Health Initiative Memory Study. Neurobiology of Aging 1996; 17 (Supl 1): S9.
16. Shumaker SA, Rebousin BA, Espeland MA, Rapp SR, McBee WL, Dailey M et al. The Women's Health Initiative Memory Study (WHIMS). Control Clin Trials 1998; 6: 604-621.
17. Wickelgren I. Estrogen stakes claim to cognition. Science 1997; 5313: 675-678.
18. Melton L. Oestrogen shields brain from ageing. Lancet 1999; 354: 1101.
19. Simpkins JA, Green PS. Estrogens: pleiotrophic anti-Alzheimer disease therapy. Toward a comprehensive theory for Alzheimer's disease. Position Papers. Potomac: Khachaturian Radebaugh and Associates, 1999: 34-40.
20. Garcia-Segura LM, Chowen JA, Dueñas M, Parduez Z, Naftolin F. Gonadal steroids and astroglial plasticity. Cell Mo Neurobiol 1996; 16: 225-237.
21. Yaffe K, Sawaya G, Liebergurg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 9: 688-695.
22. Azcoitia J, Sierra A, García-Segura LM. Localization of estrogen receptor betaimmunoreactivity in astrocytes of the adult rat brain. Glia 1999; 26: 260-267.
23. Isoe K, Ji Y, Urakami K, Adachi Y, Nakashima K. Genetic association of estrogen receptor gene polymorphism with Alzheimer's disease. Alzheimer's Res 1997; 3: 195-197.
24. Maruyama H, Toji H, Harrington CR, Sasaki K, Izumi Y, Ohnuma T et al. Lack of an association of estrogen receptor α gene polymorphism and transcripcional activity with Alzheimer disease. Arch Neurol 2000; 57: 236-240.
25. Genazzani A. Hormone replacement therapy: effects on neurotransmitters, neuropeptides, neurosteroids and the quality of life. Menopause Review 1999; 6: 10-21.
26. Collins P, Webb C. Estrogen hits the surface (News and Views). Nat Med 1999; 5: 1130-1131.
27. Valverde M, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI et al. «Acute activation of Maxi-K channels (hSlo) by stradiol is depending to the β subunit. Science 1999; 285: 1929-1931.
28. DeKosky ST. Molecular and pathological mechanisms in Alzheimer's disease. Education Program Syllabus American Academy of Neurology 1999; 3 FC.007: 66-82.
29. Selkoe DJ. Biology of β-amyloid precursor protein and the mechanism of Alzheimer disease. En: Jerry PD, Katzman R, Bick KL, Sisodia SS, editores. Lippincot Williams and Wilkins, 1999; 293-310.
30. Martinez-Lage JM. Significado de la variación genética de la apolipoproteina E en la enfermedad de Alzheimer [editorial]. Med Clin (Barc) 1999; 113: 449-451.
31. Inestrosa NC, Marzolo MP, Bonnefont AB. Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol 1998; 1: 73-86.
32. Stone DJ, Rozovsky I, Morgan TE, Anderson CP, Hajian H, Finch CE. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp Neurol 1997; 2: 313-318.
33. Varios autores. Vascular factors in Alzheimer's disease. Alzheimer's Reports 1999; 2 (Supl 1): S9-S80.
34. Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Disease and Associated Disorders 1999; 13 (Supl 3): S106-S114.
35. Kalaria RN, Ballard C. Overlap between pathology of Azheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders 1999; 13 (Supl 3): S115-S123.
36. Gurwitz D. Oestrogen replacement therapy in postmenopausal women [carta]. Lancet 1999; 9153: 674-675.
37. Palmon SC, Williams MJ, Littleton Kearney MT, Traystman RJ, Kosk Kosicka D, Hurn PD. Estrogen increases cGMP in selected brain regions and in cerebral microvessels. J Cereb Blood Flow Metab 1998; 11: 1248-1252.
38. Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T. Reduction of serum uric acid by hormone replacement therapy in post-menopausal women with hyperuricemia. Lancet 1999; 354: 650.
39. Sho-Hua Y, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 2000; 31: 745-750.
40. Sampei K, Goto S, Alkayed NJ, Crain BJ, Korach K, Traystman RJ et al. Stroke in estrogen receptor-α-deficient mice. Stroke 2000; 31: 738-744.
41. Ohkura T, Teshima Y, Isse K, Matsuda H, Inoue T, Sakai Y et al. Estrogen increases cerebral and cerebral blood flows in postmenopausal women. Menopause 1995; 1: 13-18.
42. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998; 2: 171-182.
43. Bishop J, Simpkins J. Estradiol enhances brain glucose uptake in ovariectomized rats. Brain Res Bull 1995; 36: 315-320.
44. Keller JN, Germeyer A, Begley JG, Mattsen MP. 17β-estradiol attenuates oxidative impairment of synapsis Na/K-ATPase activity, glucose transport and glutamate transport induced by amyloid β-peptide and iron. J Neurosci Res 1997, 50: 522-530.
45. Eberling JL, Jagust WJ, Reed BR, Baker MG. Reduced temporal lobe blood flow in Alzheimer's disease. Neurobiol Aging 1992; 13: 483-491.
46. Okhura T, Isse K, Akazawa K, Hamamoto M, Yavi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of Alzheimer's type. Endocr J 1994; 41: 361-371.
47. Pantoni L, García J. Cognitive impairment and cellular/vascular changes in the cerebral white matter. Ann NY Acad Sci 1997; 826: 92-102.
48. Schmidt R, Fazekas F, Reinhart B, Kapeller P, Fazekas G, Offenbacher H et al. Estrogen replacement therapy in older women: a neuropsychological and MRI study J Amer Geriatr Soc 1996; 44: 1307-1313.
49. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (Lond) 1999; (Supl 6738): A23-A31.
50. Jaffe AB, Toran Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein J Biol Chem 1994; 18: 13065-13068.
51. Green PS, Gridley KE, Simpkins JW. Estradiol protects against β-amyloid (25-35)-induced toxicity SK-N-SH human neuroblastoma cells. Neurosci Lett 1996; 3: 165-168.
52. Gridley KE, Green PS, Simpkins JW. A novel, synergistic interaction between 17β-estradiol and glutathione in the protection of neurons against β-amyloid 25-35-induced toxicity in vitro. Mol Pharmacol 1998; 5: 874-880.
53. Shi J, Panickar KS, Yang SH, Rabbani O, Day AL, Simpkins JW. Estrogen attenuates over-expression of β-amyloid precursor protein messager RNA in an animal model of focal ischemia. Brain Res 1998; 1-2: 87-92.
54. Pike CJ. Estrogen modulates neuronal Bcl-xL expression and β-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem 1999; 4: 1552-1563.
55. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nat Med 1998; 4: 447-451.
56. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Warg R et al. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides. Proc Natl Acad Sci USA 2000; 97: 1202-1205.
57. García-Segura LM, Wozniak A, Azcoitia J, Rodríguez JR, Hutchinson RE, Hutchison JB. Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair. Neuroscience 1999; 89: 567-578.
58. Mor G, Nilsen J, Hervath T, Bechmann I, Brown S, García-Segura LM et al. Estrogen and microglia. A regulatory system that affects the brain. J Neurobiol 1999; 40: 484-496.
59. o. 99-4664.
60. Markesbery WR. The role of oxidative stress in Alzheimer's disease. Arch Neurol 1999; 56: 1449-1452.
61. Markesbery WR. The role of oxidative stress in Alzheimer disease [revisión]. Arch Neurol 1999; 56: 1449-1452.
62. Behl C, Widmann M, Trapp T, Holsboer F. 17β-estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Commun 1995; 2: 473-482.
63. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 1998; 5: 707-719.
64. Miller DB, Ali SF, O'Callaghan JP, Laws SC. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci USA 1998; 153-165.
65. Santanam N, Shern Brewer R, McClatchey R, Castellano PZ, Murphy AA, Voelkel S et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998; 11: 2111-2118.
66. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997; 4: 535-541.
67. Hall ED. Editorial comment. Stroke 2000; 31: 160.
68. Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000; 31: 161-168.
69. o ed.). Filadelfia: Lippincot Williams, 1999; 373-388.
70. Toran Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992; 10: 4668-4672.
71. Toran Allerand CD. The estrogen/neurotrophin connection during neural development: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev Neurosci 1996; 1: 36-48.
72. Sohrabji F, Greene LA, Miranda RC, Toran Allerand CD. Reciprocal regulation of estrogen and NGF receptors by their ligands in PC12 cells. J Neurobiol 1994; 8: 974-988.
73. Brinton RD. 17β-estradiol induction of filopodal growth in cultured hippocampal neurons within minutes of exposure. Moll Cell Neurosci 1993; 6: 36-46.
74. Singh M, Setalo G Jr, Guan X, Warren M, Toran Allerand CD. Estrogen-induced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci 1999; 4: 1179-1188.
75. Murphy DD, Segal M. Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA 1997; 4: 1482-1487.
76. Gibbs RB. Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain. Brain Res 1999; 844: 20-27.
77. Azcoitia J, Sierra A, García-Segura LM. The neuroprotective effects of estradiol in the adult rat hippocampus: interaction with insulin-like growth factor-1 signalling. J Neurosci Res 1999; 58: 815-822.
78. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 12: 7680-7687.
79. Woolley CS, Weiland NG, McEwen BS, Schwartzkroin PA. Estradio increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic soine density. J Neurosci 1997; 5: 1848-1859.
80. Brinton RD, Proffitt P, Tran J, Luu R. Equilin, a principal component of the estrogen replacement therapy premarin, increases the growth of cortical neurons via an NMDA receptor-dependent mechanism. Exp Neurol 1997; 2: 211-220.
81. Brinton RD, Tran J, Proffitt P, Montoya M 17β-estradiol enhances the outgrowth and survival of neocortical neurons in culture. Neurochem Res 1997; 11: 1339-1351.
82. Singer CA, Figueroa-Masot XA, Batchelor RH, Clarkson TB. The mitogen activated protein kinase after glutamate excitotoxicity in primary cortical neurons. J Neurosci 1999; 19: 2455-2463.
83. Bishop J, Simpkins JW. Estradiol treatment increases viability of glioma and neuroblastoma cells in vitro. Mol Cell Neurosci 1994; 4: 303-308.
84. Schughrue P, Dorsa M. Estrogen modulates the growth-associated protein GAP-43 (neuromodulin) mRNA in the rat preoptic area and basal hypothalamus. Neuroendocrinology 1993; 57: 439-447.
85. Martínez Lage JM. Patología bioquímica en la enfermedad de Alzheimer: déficit de neurotransmisores. En: Alberca R, López Pousa S, editores. Enfermedad de Alzheimer y otras demencias. Madrid: Panamericana, 1998; 203-216.
86. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994; 2: 305-312.
87. Gibbs RB. Effects of estrogen on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment. Brain Res 1997; 1: 10-16.
88. McMillan PJ, Singer CA, Dorsa DM. The effects of ovariectomy and estrogen replacement on IrkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. J Neurosci 1996; 5: 1860-1865.
89. O'Malley CA, Hautamaki RD, Kelley M, Meyer EM. Effects of ovariectomy and estradiol benzoate en high affinity choline uptake, Ach synthesis, release from rat cerebral cortical synaptosomes. Brain Res 1987; 2: 389-392.
90. Rabbani O, Panickar KS, Rajakumar G, King MA, Bodor N, Meyer EM et al. 17β-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Exp Neurol 1997; 1: 179-186.
91. Dohanich GP, Fader AJ, Javorsky DJ. Estrogen and estrogen-progesterone treatment counteract the effect of scopolamine on reinforced T-maze alternation in female rats. Behav Neurosci 1994; 5: 988-992.
92. Gibbs RB, Burke AM, Johnson DA. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention. Horm Behav 1998; 2: 112-125.
93. Bicknell RJ Sex-steroid actions on neurotrasmission. Curr Opin Neurol 1998; 6: 667-671.
94. Gibbs RB, Aggarwal P. Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Horm Behav 1998; 2: 98-111.
95. McEwen BS, Alves SE, Bullock K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997; 5 (Supl 7): S8-S15.
96. Simpkins JW, Green PS, Gridle KE. Fundamental role for estrogens in cognition and neuroprotection. En: Decker MW, editor. Pharmalogical Treatment of Alzheimer's Disease. Nueva York: Wiley-Liss, 1997; 503-524.
97. Emiiien G, Maloteaux JM, Beyreuther K, Masters C, Alzheimer disease: mouse models are the way for therapeutics opportunities. Arch Neurol 2000; 57: 176-181.
98. Orake EB, Henderson VW, Stanczyk FZ, McCleary CA, Brown WS, Smith CA et al. Association between circulating sex steroid hormones and cognition in normal elderly women. Neurology 2000; 54: 599-563.
99. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J Am Geriatr Soc 1999; 5: 518-523.
100. Barrett Connor E, Kritz Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 20: 2637-2641.
101. Kempen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994; 6: 979-983.
102. Paganini Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, other factors on a clock drawing task in older women. J Am Geriatr Soc 1996; 7: 818-822.
103. Schmidt R, Fazekas F, Reinhart B, Kapeller P, Fazekas G, Offenbacher H et al. Estrogen replacement therapy in older women: a neuropsychoogical and brain MRI study. J Am Geriatr Soc 1996; 44: 1307-1313.
104. Ditkoff E, Crary W, Cristo M, Lobo R. Estrogen improves psychological functions in asymptomatic postmenopausal women. Obstet Gynecol 1991; 78: 991.
105. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992; 17: 485-495.
106. Szklo M, Cerhan J, Diez Roux AV, Chambless L, Cooper L, Folsom AR et al. Estrogen replacement therapy and cognitive functioning in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1995; 11: 1048-1057.
107. Nappi RE, Sinforiani E, Mauri M, Bono G, Polatti F, Nappi G. Memory functioning at menopause: impact of age in ovariectomized women. Gynecol Obstet Investigation 1999; 1: 29-36.
108. Sherwin BB. Estrogen effects on cognition in menopausal women. Neurology 1997; 5 (Supl 7): S21-S26.
109. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology 1997; 1491-1497.
110. Jacobs DM, Tang MX, Stern Y, Sano M, Marder K, Bell KL et al Cognitive function in non-demented older women who took estrogen after menopause. Neurology 1998; 2: 368-373.
111. Sherwin BB. Estrogenic effects on memory in women. Ann NY Acad Sci USA 1994; 213-230.
112. Liaño H. Cerebro de hombre, cerebro de mujer. Barcelona: Grupo Zeta, 1998; 205.
113. Shaywitz SE, Shaywitz BA, Pugh KR, Fulbright RK, Skudlarski P, Mencl WE et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1998; 13: 1197-1202.
114. Ross JL, Roeltgen D, Feuillan P, Kushner H, Cutler GB. Use of estrogen in young girls with Turner syndrome. Effects on memory. Neurology 2000; 54: 164-170.
115. Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology 1998; 4: 996-1002.
116. Sobow T, Kutter EP, Kloszewska I. Hormonal decline indicator in women (age of menopause) modifies age of onset in sporadic Alzheimer's disease. Alzheimer's Reports 1999; 2: 27-29.
117. Richards M, Kuh D, Hardy R, Wadsworth M. Lifetime cognitive function and timing of the natural menopause. Neurology 1999; 2: 308-314.
118. Paganini Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994; 3: 256-261.
119. Brenner DE, Kukull WA, Stergachis A, Van Belle G, Bowen JD, McCormick WC et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 1994; 3: 262-267.
120. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter J. Estrogen replacement therapy in older women. Arch Neurol 1994; 51: 896-900.
121. Mortel K, Mayor J. Lack of postmenopausal estrogen therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995; 7: 334-337.
122. Paganini Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch Intern Med 1996; 19: 2213-2217.
123. Tang MX, Jacobs D, Stern Y, Marcer K, Schofield P, Gurland B et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 9025: 429-432.
124. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 6: 1517-1521.
125. Waring SC, Rocca WA, Petersen RC, O'Brien PC, Tangalos EG, Kokmen E. Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology 1999; 53: 965-970.
126. Slooter AJ, Bronzova J, Witterman JCM, Van Broeckhoven C, Hofman A, Van Duijn CM. Estrogen use and early onset Alzheimer's disease: a population-based study. J Neurol Neurosurg Psychiatry 1999; 67: 779-781.
127. Henderson VW. Estrogen, cognition, a woman's risk of Alzheimer's disease. Am J Med 1997; 3: S11-S18.
128. Henderson VW. The epidemiology of estrogen replacement therapy and Alzheimer's disease. Neurology 1997; 5 (Supl 7): S27-S35.
129. Giacobini E Aging, Alzheimer's disease, estrogen therapy. Exp Gerontol 1998; 7: 865-869
130. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenoapausal women. Horm Behav 1995; 8: 312-321.
131. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc 1994; 129: 919-922.
132. Barrert Connor E, Kritz Silverstein D. Gender differences in cognitive function with age: the Rancho Bernardo study. J Am Geriatr Soc 1999; 2: 159-164.
133. Paganini-Hill A. Alzheimer's disease in women: can estrogen play a preventive role? Menopaus Rev 1999; 4: 68-76.
134. Paganini Hill A. Alzheimer's disease, women and estrogen replacement therapy. Contemp OB/GYN 1999; 110-127.
135. Editors. Study to test whether estrogen delays Alzheimer's. Neurological Diseases and Disorders Weekly 1999; 18.
136. Lindamer LA. The effect of estrogen and related compounds on cognitive performance in older women. Internat Psycogeriatrics 1999; 11 (Supl 1): resumen 4-22-2.
137. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975; 2: 293-306.
138. Fillit H, Weinreb H, Cholst I, Luine VN, McEwen BS, Amador R et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986; 3: 337-345.
139. Honjo H, Ogino Y, Naitoh K, Urabe M, Kitawaki J, Yasuda J et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989; 1: 521.
140. Honjo H, Ogino Y, Naitoh K, Urabe M, Kitawaki J, Yasuda J et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia-Alzheimer's type. A placebo controlled double blind study. J Jpn Menopause Soc 1993; 5: 167-171.
141. Okhura T, Isse K, Akazawaka K, Hamamoto M, Yaoi Y, Hagin N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994; 4: 361-371.
142. Okhura T, Isse K, Akazawa K, Yaoi Y, Hagino N. Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer's type: seven case-reports. Dementia 1995; 6: 99-101.
143. Henderson VW, Watt L, Buckwalter JG. «Cognitive skills associated with estrogen replacement in women with Alzheimer's disease» Psychoneuroendocrinology 1996; 4: 421-430.
144. Doraiswamy PM, Bieber F, Kaiser L, Krishan KR, Reuning-Scherer J, Gulanski B. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive perfomance in multicenter Alzheimer's disease trial. Neurology 1997; 48: 1511-1517.
145. Mulnard RA, Cotman CW, Klawas C, van Dyck H, Sano M, Doody R et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000; 283: 1007-1015.
146. Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D et al. Estrogen for Alzheimer's disease in women. Randomized, double-blind, placebo-controlled trial. Neurology 2000; 54: 295-301.
147. Honjo H, Tanaka K, Kashiwagi T, Urabe M, Okada H, Hayashi M et al. Senile dementia-Alzheimer's type and estrogen. Horm Metab Res 1995; 4: 204-207.
148. Honjo H, Iwasa K, Urabe M. Hormone replacement therapy and Alzheimer's disease. Menopause Rev 1999; 4: 77-85.
149. Birge SJ. The role of ovarian hormones in cognition and dementia. Neurology 1997; 51 (Supl 7): S1.
150. Birge SJ. The role of estrogen in the treament of Alzheimer's disease. Neurology 1997; 5 (Supl 7): S36-S41.
151. Stracciari A, Guarino M, Ruozzi E, D'Alessandro R, Altieri P, De Aloysio D. An open trial on transdermal estrogen therapy in post-menopausal women with Alzheimer' disease. Alzheimer's Reports 1999; 2: 17-22.
152. Shyawitz BA, Shyawitz SE. Estrogen and Alzheimer disease. Plausible theory, negative clinical trial. JAMA 2000; 283: 898-1004.
153. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996; 6: 1580-1584.
154. Schneider SL, Farlow M. Combined tracrine and estrogen replacement therapy in patients with Alzheimer's disease. Ann NY Acad Sci USA 1997; 317-322.
155. Relkin N, Orazem J, McRae T. The effect of concomitant Donepezil and estrogen treatment on the cognitive performance of women with Alzheimer's disease. Neurology 1999; 52 (Supl 2): A397.
156. Doraisway PM, Steffens DC. Combination therapy for early Alzheimer's disease: what are we waiting for? J Am Geriatr Soc 1998; 10: 1322-1324.
157. Yaffe K, Haan M, Byers A, Kuller L. Duration of estrogen use, apolipoprotein E and cognitive decline: the cardiovascular health study. Neurology 1999; 52 (Supl 2): A298.
158. Prasad KN, Cole WC, Howland AR, Prasad KC, Nahreini P, Kumar B et al. Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale. Curr Opin Neurol 1999; 12: 761-800.
159. Saunders-Pullman R, Gordon-Elliot J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement o early Parkinson's disease. Neurology 1999; 7: 1417-1421.
160. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients: a cross-over study. Neurology 1999; 53: 91-95.
161. Marder K, Tang MX, Alfaro B, Mejia H, Cote L, Jacobs D et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998; 4: 1141-1143.
162. Kompoliti K. Estrogen and movement disorders. Clin Neuropharmacol 1999; 22: 318-326.
163. Clinical Synthesis Panel on HRT. Hormone replacement therapy. Lancet 1999; 354: 152-155.
164. Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet 2000; 355: 566-569.
165. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
166. Willet WC, Colditz G, Stampfer M. Postmenopausal estrogens-opposed, unopposed or none of above. JAMA 2000; 283: 324-329.
167. Wren BG. Megatrials of hormonal replacement therapy. Drug Aging 1998; 12: 343-348.
168. Beckman CR Alzheimer's disease: an estrogen link? Curr Opin Gynecol 1997; 5: 295-299.
169. Skolnic A. Evaluating estrogen for Alzheimer's disease poses ethical and logistical challenges. JAMA 1997; 277: 1832-1833.
170. Braak H, Braak E. Staging of Alzheimer's disease related neurofibrillary changes. Neurobiol Aging 1995, 3: 271-278.
171. Price JL, Morris JC. Tangles and plaques in non-demented aging and «preclinical» Alzheimer's disease. Ann Neurol 1999; 3: 358-368.
172. Green PS, Gordon K, Simpkins JW. Phenolic, a ring requirement for the neuroprotective effects of estrogens. J Steroid Biochem Mol Biol 1997; 14: 229-235
173. Moosman B, Behl C. The antioxidant neuroprotective effects of estrogen and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999; 96: 8867-8872.